FDAnews
www.fdanews.com/articles/177217-median-technologies-microsoft-ink-collaborative-agreement

Median Technologies, Microsoft Ink Collaborative Agreement

June 22, 2016

MEDIAN Technologies has entered into a collaborative agreement with Microsoft to create cancer detection, diagnosis and monitoring solutions using Big Data analytics.

Under the agreement, the companies will install Median’s biomarker phenotyping system — IBIOPSY — on the Microsoft Azure cloud computing platform, the companies said.

The combination will allow the companies to process and analyze images, and detect disease biomarkers in real time.

Financial terms of the agreement were not disclosed. — Anisa Jibrell

View today's stories